Since most FH patients in these studies have heterozygous mutation in the LDLR gene, an interesting question arises as to whether LDLR mediated cellular cholesterol metabolism is involved with the diabetogenic effect of statins (Preiss and Sattar, 2015; Besseling and Hutten, 2016). The gene discussed is LDLR; the disease is familial hyperaldosteronism.